Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 7/20 | 0.40 |
| ▸ | BCR | P11274 | 7/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 9/20 | 0.37 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12397363 | 0.90 | ABL1 (0.44) | ABL1BCRBRAF | |
| SCHEMBL12397372 | 0.90 | ABL1 (0.42) | ABL1BCRABCG2BRAFGPR142 | |
| SCHEMBL12397355 | 0.90 | ABL1 (0.46) | ABL1BCRBRAF | |
| SCHEMBL12397347 | 0.90 | ABL1 (0.46) | ABL1BCRBRAF | |
| SCHEMBL12397291 | 0.89 | ABL1 (0.51) | ABL1BCR | |
| SCHEMBL12464981 | 0.89 | ABL1 (0.40) | ABL1BCRABCG2BRAFGPR142 | |
| SCHEMBL12464937 | 0.88 | ABCG2 (0.40) | ABL1BCRABCG2BRAFGPR142 | |
| SCHEMBL12397339 | 0.88 | BRAF (0.41) | ABL1BCRABCG2BRAFGPR142 | |
| SCHEMBL12397366 | 0.88 | ABL1 (0.40) | ABL1BCRABCG2BRAFGPR142 | |
| SCHEMBL17612970 | 0.87 | BRAF (0.38) | ABL1BRAFMAPTCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2173734-B1 | CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2016-03-23 | — | — | EP | disclosed |
| US-8889665-B2 | Chemical compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-18 | — | — | US | disclosed |
| US-8889665-B2 | Chemical compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-18 | — | — | US | disclosed |
| US-20110183952-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-28 | — | — | US | disclosed |
| US-20110183952-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183952-A1 | NEW CHEMICAL COMPOUNDS | MKI67, CCNA1, CCNT1 | ABL1 136/4885BCR 922/4885ABCG2 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.